Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study
Jemma M. Boyle, Gemma Hegarty, Christopher Frampton, et al.
European Journal of Cancer (2021) Vol. 155, pp. 136-144
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

ESMO Guidance for Reporting Oncology real-World evidence (GROW)
Luís Castelo-Branco, Anna Pellat, Diogo Martins-Branco, et al.
Annals of Oncology (2023) Vol. 34, Iss. 12, pp. 1097-1112
Open Access | Times Cited: 95
Scientific evidences of anticancer potential of medicinal plants
Subhash Chandra, Manoj Gahlot, Alka Choudhary, et al.
Food Chemistry Advances (2023) Vol. 2, pp. 100239-100239
Open Access | Times Cited: 55
European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission
Mark Lawler, Lynne Davies, Simon Oberst, et al.
The Lancet Oncology (2022) Vol. 24, Iss. 1, pp. e11-e56
Open Access | Times Cited: 68
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy
Teja Voruganti, Pamela R. Soulos, Ronac Mamtani, et al.
JAMA Oncology (2023) Vol. 9, Iss. 3, pp. 334-334
Closed Access | Times Cited: 36
Changes in survival in de novo metastatic cancer in an era of new medicines
Marianne Luyendijk, Otto Visser, Hedwig M. Blommestein, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 115, Iss. 6, pp. 628-635
Open Access | Times Cited: 28
Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs
Renata Iskander, Hannah Moyer, Karine Vigneault, et al.
JAMA (2024) Vol. 331, Iss. 24, pp. 2105-2105
Closed Access | Times Cited: 16
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility
Daichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e230698-e230698
Open Access | Times Cited: 18
ESMO Guidance for Reporting Oncology real-World evidence (GROW)
Luís Castelo-Branco, Anna Pellat, Diogo Martins-Branco, et al.
ESMO Real World Data and Digital Oncology (2023) Vol. 1, pp. 100003-100003
Open Access | Times Cited: 15
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit
Mark P. Lythgoe, Jonathan Krell, Mark Bower, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 4, pp. e150-e160
Open Access | Times Cited: 12
Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments
Dario Trapani, Kiu Tay-Teo, Megan E. Tesch, et al.
Current Oncology (2022) Vol. 29, Iss. 8, pp. 5774-5791
Open Access | Times Cited: 17
Post‐Market Evidence for Cancer Medicines in Regulatory and Clinical Decision‐Making: A Scoping Review
Eliza J. McEwin, Ashleigh Hooimeyer, Barbara Mintzes
Pharmacoepidemiology and Drug Safety (2025) Vol. 34, Iss. 1
Closed Access
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients
Tae Hata, Tadaaki Yamada, Yasuhiro Gotô, et al.
Lung Cancer (2025), pp. 108104-108104
Closed Access
The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms
A Vidalis, Oscar Dumoulin, Mousumi Bose Godbole, et al.
International Journal of Technology Assessment in Health Care (2025) Vol. 41, Iss. 1
Closed Access
A comprehensive review of traditional medicinal plants and their role in ovarian cancer treatment
Banuppriya Palani, Renu Vajjiravelu, Rajeshkumar Shanmugam, et al.
South African Journal of Botany (2025) Vol. 181, pp. 426-445
Closed Access
Supply chain 4.0 technologies for value creation in pharmaceutical industry
Prabakaran Yogeswaran, Rohit Kumar Singh, Sachin Modgil
Journal of Global Operations and Strategic Sourcing (2025)
Closed Access
Cancer medicines: a private vice for public benefit?
Richard Sullivan
ecancermedicalscience (2024) Vol. 18
Open Access | Times Cited: 3
Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022)
Jeroen W. G. Derksen, Diogo Martins-Branco, Antonios Valachis, et al.
ESMO Real World Data and Digital Oncology (2024) Vol. 4, pp. 100039-100039
Closed Access | Times Cited: 3
Augmenting randomized clinical trial data with historical control data: Precision medicine applications
Boris Freidlin, Edward L. Korn
JNCI Journal of the National Cancer Institute (2022) Vol. 115, Iss. 1, pp. 14-20
Open Access | Times Cited: 14
Can Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival?
Duxin Sun, Christian Macedonia, Zhigang Chen, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
Pharmaceutical industry relationships with oncologists in sub-Saharan Africa
Fidel Rubagumya, Miriam Mutebi, Achille Manirakiza, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 2, pp. e96-e101
Closed Access | Times Cited: 5
Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries
Murtuza Bharmal, Ioannis Katsoulis, Jane Chang, et al.
Future Oncology (2024), pp. 1-12
Open Access | Times Cited: 1
Cross-sectional analysis of use of real-world data in single technology appraisals of oncological medicine by the National Institute for Health and Care Excellence in 2011–2021
Jiyeon Kang, John Cairns
BMJ Open (2024) Vol. 14, Iss. 3, pp. e077297-e077297
Open Access | Times Cited: 1
Prevalence of involuntary treatment among community-living older persons with dementia: A systematic review
Minyan Liu, Yuqiang Wang, Qinglin Zeng, et al.
Archives of Gerontology and Geriatrics (2024) Vol. 127, pp. 105574-105574
Closed Access | Times Cited: 1
Analysis of the characteristics and the degree of pragmatism exhibited by pragmatic-labelled trials of antineoplastic treatments
Robbe Saesen, Kevin Depreytere, Karyna Krupianskaya, et al.
BMC Medical Research Methodology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 3
The Innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep?
Aris Angelis, Ajay Aggarwal, Alec Miners, et al.
Journal of the Royal Society of Medicine (2023) Vol. 116, Iss. 10, pp. 324-330
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top